AllianceBernstein’s Clearside Biomedical CLSD Stock Holding History

AllianceBernstein’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-960	Closed	-$15K	–	3117
2018 Q4	$15K	Sell	960 -487	-34%	-$22.9K	﹤0.01%	3090
2018 Q3	$133K	Hold	1,447	–	–	﹤0.01%	3050
2018 Q2	$232K	Buy	+1,447	New	+$244K	﹤0.01%	2908

Other funds holding CLSD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

AllianceBernstein's CLSD Position: Q1 2019 in Review

AllianceBernstein sold out of Clearside Biomedical (CLSD) in Q1 2019, closing a stake of 960 shares — an estimated $15K sold.

AllianceBernstein first reported a position in CLSD in Q2 2018 and held it in 3 quarters. The position peaked at $232K in Q2 2018. 57 funds tracked by Wall St. Rank hold CLSD as of Q1 2019.

AllianceBernstein reported no remaining Clearside Biomedical position as of Q1 2019 after selling out during the quarter.
AllianceBernstein sold 960 Clearside Biomedical shares in Q1 2019, an estimated $15K.
AllianceBernstein first reported a position in Clearside Biomedical in Q2 2018 and held it in 3 quarters.
AllianceBernstein's Clearside Biomedical position peaked at $232K in Q2 2018.
57 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2019.

Based on AllianceBernstein's 13F filing for Q1 2019, filed 14 May 2019.